ArticleBreast cancer (Dove Medical Press)2026
Hemodynamic Inflow-Outflow Profiling as an Integrated DCE-MRI Biomarker for Diagnosis and Risk Stratification in Breast Cancer: A Multicenter Retrospective Study.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Limitations in conventional MRI biomarkers (ADC, DCE-MRI parameters) for characterizing tumor microenvironment heterogeneity necessitate novel approaches integrating vascular remodeling dynamics. We introduce the Intratumoral-Peritumoral Inflow-Outflow (IPIO) model to address these constraints. Methods: This multicenter retrospective study developed and validated a hemodynamics-driven IPIO model using DCE-MRI kinetics in 159 patients (training: n=93; independent validation: n=66). Performance was evaluated for malignancy detection and stratification (invasive grading, molecular subtyping of TNBC, Ki-67 expression, lymph node metastasis) through ROC analysis and correlation studies. Results: IPIO demonstrated robust malignancy discrimination (AUC 0.934, 95% CI: 0.897-0.974; sensitivity 91.7%, specificity 83.3%), significantly outperforming ADC (ΔAUC +0.123, Conclusion: IPIO provides an integrated hemodynamic framework for both breast cancer diagnosis and risk stratification, with particular clinical utility for identifying triple-negative subtypes and metastatic potential. Its spatiotemporal profiling of vascular-peritumoral interactions represents a promising approach for noninvasive tumor characterization. Limitations include retrospective design and small TNBC subgroup; prospective validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.